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Tumour cells express functional lymphatic
endothelium-specific hyaluronan receptor in vitro
and in vivo: Lymphatic mimicry promotes oral
oncogenesis?
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Abstract
Lymphatic metastasis represents the main route of tumour cell dissemination in oral squamous cell carcinoma (OSCC).
Yet, there are no FDA-approved therapeutics targeting cancer-related lymphangiogenesis to date. The lymphatic
vessel endothelial hyaluronic acid receptor 1 (LYVE-1), a specific lymphatic marker, is associated with poor survival in
OSCC patients. In this study, we present a potential novel mechanism of lymphatic metastasis in OSCC—lymphatic
mimicry (LM), a process whereby tumour cells form cytokeratin+/LYVE-1+, but podoplanin-negative, mosaic
endothelial-like vessels. LM was detected in one-third (20/57; 35.08%) of randomly selected OSCC patients. The LM-
positive patients had shorter overall survival (OS) compared to LM-negative group albeit not statistically significant.
Highly-metastatic tumour cells formed distinct LM structures in vitro and in vivo. Importantly, the siRNA-mediated
knockdown of LYVE-1 not only impaired tumour cell migration but also blunted their capacity to form LM-vessels
in vitro and reduced tumour metastasis in vivo. Together, our findings uncovered, to our knowledge, a previously
unknown expression and function of LYVE-1 in OSCC, whereby tumour cells could induce LM formation and promote
lymphatic metastasis. Finally, more detailed studies on LM are warranted to better define this phenomenon in the
future. These studies could benefit the development of targeted therapeutics for blocking tumour-related
lymphangiogenesis.
Introduction
Oral squamous cell carcinoma (OSCC) is one of the
most common cancers in the head and neck region arising
anywhere in the oral cavity. Unfortunately, despite recent
advances in cancer management, the overall 5-year overall
survival (OS) rate remains stagnant at around 50%1. The
poor prognosis of OSCC patients is mainly attributed to
the invasiveness of OSCC cells and their ability to swiftly
disseminate to regional lymph nodes2. Thus, there is an
urgent need to better understand the mechanisms behind
OSCC metastasis, and to identify novel druggable targets
that can improve the survival of OSCC patients.
Vascularisation is a crucial event during tumour
development and metastasis3,4. Intratumoural vasculature
has long been thought to be formed by endothelial cells
alone. However, the seminal work of Maniotis and col-
leagues showed that aggressive uveal melanoma cells were
able to acquire endothelial cell behaviour by generating de
novo vessel-like networks independently of existing vas-
cular endothelial cells5. This novel paradigm, which is
termed vascular mimicry (VM), has sparked an enormous
interest in the field of cancer research5,6. Thenceforth,
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myriad studies have reported intriguing aspects of VM in
different types of cancer (reviewed in Hendrix et al.)6.
Interestingly, the transcriptional signature of VM-forming
tumour cells revealed remarkable phenotypic plasticity
(i.e. stemness), which facilitates transdifferentiation into
other cell types6,7. Of particular importance, current
antiangiogenic therapy remains ineffective on VM,
thereby paving the way for more selective and persona-
lised approaches7. Recently, the VM channels were shown
to represent a promising prognosticator and therapeutic
target in head and neck squamous cell carcinomas
(HNSCC)8.
Lymphatic vessels in the tumour microenvironment are
the main route of dissemination in carcinomas including
HNSCC, where tumour cells can preferentially metasta-
sise to several hundred of regional lymph nodes9,10. Fur-
thermore, lymphatic vessel density has been shown to
predict metastasis-free survival in OSCC patients better
than blood microvessel density, and hence also for guiding
future therapeutic approaches11. Mirroring angiogenesis,
tumour cells were also shown to secrete lymphangiogenic
factors that facilitate lymphangiogenesis and metastasis to
sentinel lymph nodes12. Importantly, the discovery of
specific markers for lymphatic endothelial cells (LEC),
such as the lymphatic vessel endothelial hyaluronic
acid receptor 1 (LYVE-1) and podoplanin (i.e. D2-40),
has made it possible to distinguish between lymphatic
and blood vessels10,13. Of note, LYVE‐1 bears a high
degree of specificity for lymphatic vessels, and it has
been an essential component of many important studies
on tumour-induced lymphangiogenesis13,14. Moreover,
LYVE-1 is strongly associated with nodal metastasis in
OSCC, and its antibody was able to inhibit the develop-
ment and progression of primary breast tumours15,16.
Based on the well-investigated concept of VM, we
aimed to test our hypothesis that tumour cells can attain a
LEC-like phenotype and form lymphatic vessel-like
structures (i.e. lymphatic mimicry, LM) in OSCC tissue
to facilitate tumour growth and metastasis. For this pur-
pose, LYVE-1 was adopted in our study as a lymphatic
marker using clinical samples, in vivo and in vitro
experimental approaches. We also examined whether LM
expresses other LEC markers such as D2-40.
Results and discussion
The CK+/LYVE-1+ vessel-like structures are identified in
OSCC tumours
First, we examined the presence of lymphatic vessel-like
structures (i.e. LM) in primary OSCC tumours (n= 57)
using specific tumour and LEC markers (CK and LYVE-1,
respectively). The following criteria were set to identify the
LM phenomenon in tumour tissues: (1) intratumoural
vessel- or capillary-like structures; (2) LM lining is positive
for OSCC tumour marker (CK+) staining; and (3) positive
for LEC marker (LYVE-1+) staining. Interestingly, the
OSCC tissues contained vessel-like structures lined by
CK+/LYVE-1+ cells as depicted in (Fig. 1a). In addition,
some CK+/LYVE-1+ cells were also seen as a few “hot
spots” in nests of densely packed tumour cells, where
LYVE-1 immunoreactivity was observed in the tumour cell
membrane and cytoplasm (Fig. 1b). These LM structures
were observed in 20/57 (35.08%) OSCC patients (Fig. 1c).
We then assessed whether LM structures express other
LEC markers such as D2-40, which represents, together
with LYVE-1, the most commonly used LEC markers in
HNSCC10. Also, we tested the status of CD44, which
enhances tumour aggressiveness by promoting tumour
cell plasticity and VM17. Using the multiplexed immuno-
histochemistry (mIHC), normal lymphatic vessels were
LYVE-1+/D2-40+ (Fig. 1d). However, LM structures were
strongly CK+/LYVE-1+/CD44+ but entirely lacking D2-40
immunoreactivity (Fig. 1e).
The prognostic value of LM status in OSCC patients
To investigate the clinical relevance of LM expression
with the survival and the clinicopathological parameters
of OSCC patients, we divided the patients (n= 57) into
two groups based on the LM status: positive (LM+) and
negative (LM−) groups. Interestingly, the estimated OS of
the LM+ group (58 months) was noticeably shorter
compared to the LM− group (80 months) (Supplementary
Fig. 1). Likely due to a small sample size, such difference
did not however reach a statistical significance (P=
0.351). Yet, the correlation between LM+ status with
younger age group (P= 0.016) and higher clinical T-stage
(P= 0.077) represented interesting hints (Supplementary
Table 1). The investigators were blinded to the clinical
data of the patients during the experiment and when
assessing the outcome by using samples with coded labels,
with no reference to any respective group.
Tumour cell lines express LYVE-1
To confirm that the detected intratumoural LYVE-1-
immunoreactivity was derived from tumour cells and not
from other cells (e.g. vicinal LEC), we first quantified
LYVE-1 mRNA in OSCC cells using the highly sensitive
droplet-digital PCR (ddPCR). The ddPCR reactions with
at least 13 × 103 droplets per sample were accepted for
further analysis. The absolute quantification analysis
revealed that OSCC cells express LYVE-1 gene. LYVE-1
copies were detected in the cells with high-metastatic
potential (i.e. HSC-3; 5 copies/μl) and also in the low-
metastatic SCC-25 cells (2 copies/μl) (Fig. 2a). LYVE-1
protein was also detected in both OSCC cell lines by
immunoblotting (Fig. 2b). We then utilised immuno-
fluorescence staining to assess whether monolayered
OSCC cells express LYVE-1 immunoreactivity. As
expected, LYVE-1 protein was detected in the cytoplasm
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of both OSCC cell lines (Fig. 2c). Additionally, the
expression of LYVE-1 in multiple keratinocyte and cancer
cell lines was also studied (supplementary data). We
found that these cell lines differentially express LYVE-1
in vitro when cultured as monolayers (Supplementary
Fig. 2a, b) or in a 3D organotypic myoma model (Sup-
plementary Fig. 2c).
The high-metastatic HSC-3 cells form LYVE-1+ vessel-like
structures in vitro and in vivo
After having confirmed the presence of LYVE-1 in
OSCC cell lines, we examined the ability of these cells to
create vessel-like structures on a 3D matrix. Interestingly,
when seeded on Matrigel, the high-metastatic HSC-3
formed well-defined, interconnected, ‘vessel-like' network
that resembled the early stages of endothelial cell tubu-
logenesis (Fig. 3a, b). In contrast, the low-metastatic SCC-
25 cells failed to form any consistent structures and
remained as single cells, although both cell lines were
cultured under identical experimental conditions (Fig. 3c).
Of note, such vessel-like cell networks were reminiscent
of the LM structures in OSCC patients and exhibited
stronger LYVE-1-immunoreactivity compared with the
monolayer cell cultures (Fig. 3d). To investigate the ability
of HSC-3 cells to form such LM structures in vivo, cell
suspension was injected into the lateral tongue border of
BALB/c nude male mice (n= 18), followed by double-
labelled IF on the harvested xenograft sections.
Surprisingly, CK+/LYVE-1+ vessel-like structures, similar
to those observed in patient samples, were detected in 8/
18 (44.44%) of the xenograft sections, of which three were
metastatic tumours (Fig. 3e).
LYVE-1 knockdown impedes the ability of HSC-3 to form
vessel-like structures on Matrigel
Given the crucial role of LYVE-1 in inducing lym-
phangiogenesis18, we next aimed to determine its putative
role in the formation of LM in OSCC. To this end, we
employed siRNA-mediated knockdown approach in HSC-
3 cell line, while SCC-25 cells were excluded as they failed
to form similar vessel-like networks. qPCR and western
blot analyses showed a clear attenuation of LYVE-1 in the
silenced group (Fig. 4a, b). HSC-3 cells transfected with
siRNA LYVE-1 (siLYVE-1) or siControl were cultured on
Matrigel for 24 h. Strikingly, siLYVE-1 treated cells
showed a clear impairment in their ability to form vessel-
like structures when compared to siControl cells, sug-
gesting a pivotal role of LYVE-1 in LM formation in
OSCC cells (Fig. 4c and Supplementary videos 1–3).
LYVE-1 knockdown shows moderate, non-significant,
impact on HSC-3 cell viability
To confirm that the impaired ability of siLYVE-1 cells to
form vessel-like structures is not due to cell death, we
utilised resazurin dye assay to assess the effect of LYVE-1
siRNA knockdown on HSC-3 cell proliferation and
(see figure on previous page)
Fig. 1 Lymphatic mimicry structures in primary oral squamous cell carcinoma (OSCC). a A representative figure of LM+ lymphatic vessel-like
structure. Scale bar 50 µm. A total of 57 OSCC patient primary tumour samples were stained with CK/LYVE-1 and scored as LM+ or LM− based on the
criteria detailed in the results and discussion section. The paraffin-embedded resection specimens were obtained from patients with OSCC of the
mobile tongue. Patients were treated surgically at Oulu University Hospital during the period of 2009–2016 with no other preoperative treatment.
Informed consent was obtained from all patients. The use of these samples and data enquiry were approved by the Ethics Committee of the Oulu
University Hospital and by the National Supervisory Authority for Welfare and Health (VALVIRA). For the double-label immunofluorescence (IF)
staining, deparaffinised sections of human (n= 57) and mouse (n= 18) OSCC tissues were pretreated with 10 mM Citrate buffer (pH 6) and
underwent microwave antigen retrieval in a Micromed T/T Mega Microwave Processing Lab Station (Hacker Instruments & Industries). Blocking of
non-specific binding was performed in 10% donkey normal serum (Sigma-Aldrich) for 1 h at room temperature (RT). Blocking of non-specific binding
was performed in 10% donkey normal serum (Sigma-Aldrich) for 1 h at room temperature (RT). Slides were then incubated with an antibody solution
containing 1 µg/ml polyclonal rabbit antihuman LYVE-1 antibody (HPA042953, Sigma‐Aldrich, St Louis, MO, USA), and 1:200 diluted monoclonal
mouse antihuman pan-cytokeratin (CK; DAKO, Carpinteria, CA, USA) overnight at +4 °C. Human lymph node tissue was utilised as a positive control
for LYVE-1. For negative controls, the primary antibodies were omitted or replaced with an antibody isotype control. After washing 3x in phosphate
buffered saline (PBS), slides were then incubated with: (1) donkey anti-mouse Alexa Fluor®‐568 and donkey anti-rabbit Alexa Fluor®‐488 conjugated
secondary antibodies (1:200; Vector Laboratories) for 1 h at RT and washed in PBS; (2) 4',6-Diamidino‐2‐phenylindole (DAPI; 1:2000; Sigma-Aldrich,
Germany) for 10 min at RT and washed 2 times in PBS and once in dH2O. Imaging was performed using the fully automated Leica DM6000
microscope supplied with the Leica DF365-FX camera (Leica Microsystems, Wetzlar, Germany). b A representative figure of LM+ cluster with an insert
showing that LYVE-1 immunoreactivity is detected in the tumour cell membrane and cytoplasm. Scale bar 25 µm. c The distribution of LM+ and LM−
in the clinical samples from randomly selected OSCC patients (n= 57). d A representative figure of normal lymphatic vessels in OSCC sample
mapped with different LM-relevant markers using the multiplexed immunohistochemistry (mIHC). The results revealed that normal vessels were
expressing both LYVE-1 and D2-40 with a faint expression of CD44. e A representative figure of LM+ OSCC sample mapped by the same mIHC panel.
The results revealed a strong immunoexpression of CK+/LYVE-1+/CD31+ but completely D2-40-negative in these vessel-like structures. Scale bar
50 µm. The following antibodies were included in the mIHC panel: LYVE-1 (as above); 1:100 diluted monoclonal mouse antihuman D2-40 (Dako,
Carpinteria, CA, USA); 1:100 diluted monoclonal mouse antihuman CD44 (Cell Marque, Rocklin, CA, USA); and a mix of two CK clones: (1) 1:150 diluted
C-11 (Abcam, Cambridge, UK), (2) 1:100 diluted AE1/AE3 (Dako, Carpinteria, CA, USA). The mIHC was conducted on randomly selected OSCC samples
(n= 5) from the LM+ group. The mIHC was carried out in the Digital Microscopy and Molecular Pathology Unit (FIMM institute, University of Helsinki)
as described in Blom et al.47.
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viability. Results revealed that transfection with LYVE-1
siRNA caused a modest, non-significant, decrease on the
growth of HSC-3 cells (P > 0.05; Fig. 4d).
OSCC cell migration and invasion are suppressed by LYVE-
1 knockdown
It was recently shown that endogenous LYVE-1 can
facilitate transluminal cell migration19. Thus, we assessed
the influence of LYVE-1 on the tumour cell migration, a
crucial metastatic feature, by employing the IncuCyte
scratch-wound healing assay on siLYVE-1 and siControl
OSCC cells. Notably, siLYVE-1-knocked down cells
showed a remarkable and consistent reduction in their
directed migration (i.e. relative wound density) compared
to the siControl cells (P < 0.05; Fig. 4e, f). Then, we
evaluated the pro-invasion potential of LYVE-1 by
employing the 3D organotypic myoma model20. We
found that siLYVE-1 cells had smaller invasion depth
and invasion area compared with the siControl
(Supplementary Fig. 2d–f). However, the difference was
not statistically significant (P > 0.05).
LYVE-1 knockdown significantly reduced metastasis in vivo
Next, we addressed the pivotal question of whether
LYVE-1 is a pro-metastatic in vivo by xenotransplantation
of siLYVE-1-inhibited OSCC cells into zebrafish larvae.
Indeed, zebrafish is emerging as an attractive addition
to animal models in cancer research, which provided
important data regarding metastatic events in vivo
and personalised cancer approaches21. The siLYVE-1 and
siControl HSC-3 cells, labelled with CellTrace™ Far Red
fluorochrome, were microinjected into the perivitelline
space. On the fourth day post-injection, larvae were
analysed by microscopic imaging to discern fish with a
tumour metastasised outside the yolk sac region. Intri-
guingly, the siControl group had significantly more fish
with metastasis to cloaca and tail regions compared
with the siLYVE-1 group, where tumour remains largely
Fig. 2 OSCC cell lines express the lymphatic endothelium-specific LYVE-1. a Droplet-digital PCR analysis revealed a positive expression of LYVE-1
in OSCC cell lines. The used cell lines are detailed in the supplementary materials. The ddPCR was performed as recently reported48. The LYVE-1
primers were designed using the Primer-BLAST tool (powered by Primer3) in NCBI website. The primers were checked by BLAST analysis to avoid any
non-specific binding. The LYVE-1 primer sequences were as follows: forward 5′-GTGAGCAAAAAGGCGAACC-3′; reverse 5′-AATCCATCTCCAACCCAGC-
3′. Detection of positive droplets and data analysis were performed using QX200™ Droplet Digital™ PCR Systems (Bio-Rad Laboratories) and
QuantaSoft software (version 1.7.4.0917; Bio-Rad Laboratories) according to the manufacturer’s instructions. b The LYVE-1 protein was also detected in
both OSCC cell lines by immunoblotting. The immunoblotting details can be found in the supplementary materials. c Double IF staining revealed
positive LYVE-1 immunoreactivity in both OSCC cell lines. HSC-3 and SCC-25 cells were cultured on coverslips, washed in PBS and fixed using 4%
paraformaldehyde. Cells were then stained with the same LYVE-1 antibody as above, and incubated with Alexa Fluor™-568 Phalloidin for filamentous
actin (F-actin; 1:200; Thermo Fisher Scientific) for 30 min at RT. Next, cells were stained with DAPI (1:2000) and mounted with ProLong® Gold Antifade
Mountant (Thermo Fisher Scientific). Scale bar 200 µm.
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confined within the yolk sac area (61.1 vs. 24.1%,
respectively; P < 0.05) (Fig. 4g, h).
The main cause of cancer-related mortality is metas-
tasis, a process mediated by the access of cancer cells to
blood and lymphatic vasculatures22. Indeed, the identi-
fication of tumour cell-derived VM, as a novel model of
neovascularization, has opened a new perspective in
cancer research23. Increasing evidence shows that VM is
strongly associated with poor survival in cancer patients,
and hence represents an attractive therapeutic tar-
get8,23,24. Interestingly, in OSCC tumour tissues, we
observed a phenomenon that could be similar to the
VM. About one-third of randomly selected OSCC
patients had vessel-like structures with surrounding
CK+/LYVE-1+ cells. These structures were expressing
LYVE-1 but, unlike normal LEC, they were entirely
negative for D2-40, implying a key role of LYVE-1 in
their development. Patients with these structures had
seemingly worse survival outcome and higher clinical T-
stage. However, the sample size in this report may not be
large enough to reach a statistically significant difference
between the LM groups. More studies with larger patient
samples, across different populations, should thus be
conducted to reach a resounding conclusion. Further-
more, although LYVE-1 was expressed in OSCC cell
lines, only the high-metastatic cells (HSC-3) were able to
form similar LYVE-1+ vessel-like structures in vitro and
in vivo. Importantly, LYVE-1 knockdown in these cells
has markedly blunted their ability to form such struc-
tures and reduced their migration, invasion and metas-
tasis without a robust impact on cell viability. These
findings may indicate a novel potential mechanism
underlying tumour growth and metastasis in OSCC—
LM (Supplementary Fig. 3).
Unlike sarcomas, carcinomas including HNSCC utilise
lymphatic vessels as the preferential route of metastasis
by initially spreading to the regional cervical lymph
nodes9,10. Therefore, the presence of cervical lymph node
metastases is considered one of the most important
prognostic indicators in OSCC patients25. In this regard,
the localisation of lymphatic vessels in the tumour
tissue matters. Intratumoural LYVE-1+ lymphatic vessels,
unlike the peritumoral ones, were indeed associated with
higher relapse rate and poor disease-specific survival in
HNSCC patients26. To our knowledge, the present study
is the first to report intratumoural CK+/LYVE-1+ mosaic
vessel-like structures in OSCC tumours. In support of
our findings, it was recently shown that aggressive breast
cancer cells can form intratumoural LM channels to
access lymphatic vasculature27. These channels were
concomitantly positive for tumour and lymphatic vessel
markers including cytokeratin and LYVE-1, respec-
tively27. Furthermore, we found that multiple keratino-
cytes and cancer cell lines differentially express LYVE-1
in vitro—a trait not widely discussed before. Interestingly,
such expression levels and localisation of LYVE-1 were
also retained in the 3D organotypic myoma model. The
functional effects of LYVE-1 in cancer cells pose an
interesting avenue for studies on cancer cell plasticity and
metastatic potential.
The VM structures are traditionally identified in
tumour tissues as periodic acid-Schiff positive (PAS+)
vessel-like spaces, with the absence of any specific endo-
thelial cell markers28. However, this method has been
criticised for its limited specificity. In fact, PAS staining
detects extracellular matrix components, and hence PAS+
regions may also represent non-functional structures
irrelevant to VM29,30. On the other hand, the mosaic
(see figure on previous page)
Fig. 3 The high-metastatic HSC-3 cells form LYVE-1+ vessel-like structures in vitro and in vivo. a Endothelial cell tubulogenesis formed by
Matrigel-seeded human umbilical vein endothelial cells (HUVEC). b Matrigel-seeded HSC-3 cells formed well-defined, interconnected, vessel-like
network that resembled the structures formed by HUVEC. c On contrary, the low-metastatic SCC-25 cells remained as single cells and failed to form
any consistent vessel-like structures on Matrigel. Scale bar 100 µm. In brief, HUVEC and OSCC cells were first suspended in serum-free medium and
seeded at a density of 20 × 103 cells/well in 96-well plates pre-coated with 9.375 mg/ml Matrigel® basement membrane matrix (Corning, New York,
USA). Cells were then incubated for 24 h at +37 °C. d The HSC-3-formed vessel-like cell networks were strongly LYVE-1+ particularly at the tubular
extensions and intercellular junctions. Scale bar 100 µm. Matrigel-seeded cells were first fixed in 4% paraformaldehyde (Santa Cruz) for 20 min at RT
and washed once in PBS. Next, samples were incubated in normal serum for 1 h at RT, and the staining continued as aforementioned above. e The
xenograft mice model of OSCC revealed formation of CK+/LYVE-1+ vessel-like structures by HSC-3 cells in the harvested tumour sections. Scale bar
50 µm. Human HSC-3 cells were detached, suspended in cold serum-free DMEM and then mixed with a cold Matrigel at 1:1 to a final concentration
of 8 × 106 cells/ml. BALB/c nude male mice (Charles River, Germany) were anaesthetised at age of 7 weeks via subcutaneously administered mixture
of 0.5 mg ketamine and 0.1 mg xylazine hydrochloride. More details are described in the supplementary materials. Sections from 18 mice comprised
primary (n= 9) and metastatic (n= 9) tumours were used for double-label IF staining as described before. The investigators were blinded to the
animal group allocation during the experiment and when assessing the outcome by using samples with coded labels with no reference to any
respective group. The experiments followed the ARRIVE guidelines and were conducted in accordance with the European Convention for the
Protection of Vertebrate Animals for Experimental and Other Scientific Purposes´ guidelines on accommodation and care of animals. Cell culture
imaging was performed using a Zeiss digital AxioCam ERc5s camera connected to Zeiss Axioplan microscope (Carl Zeiss Microscopy GmbH, Jena,
Germany). Cell culture imaging was performed using a Zeiss digital AxioCam ERc5s camera connected to Zeiss Axioplan microscope (Carl Zeiss
Microscopy GmbH, Jena, Germany).
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vessel-like pattern, where tumour and endothelial cell
markers are simultaneously expressed, has gained atten-
tion not only for identifying VM but also as a prognostic
marker31,32. This mosaic pattern was long thought to be
formed by a coalescence of tumour and endothelial cells
during carcinogenesis 31. However, recent studies revealed
that aggressive tumour cells can express genes associated
with non-cancerous cell phenotype, such as endothelial
cell precursors33,34.
Phenotype plasticity allows cancer cells to reversibly
transform phenotypes and acquire functional adaptation
to thrive in a harsh tumour microenvironment33,35,36. For
instance, glioblastoma cancer cells were able to differ-
entiate into functional CD31+ endothelial cells, which
Fig. 4 (See legend on next page.)
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created VM structures in a xenograft mouse model37.
Likewise, breast cancer stem-like cells differentiated into
endothelial cells and formed vessel-like structures on
Matrigel38. Consistently with these reports, we show that
LYVE-1 is expressed by OSCC cell lines, but only HSC-3
cells, and not the less aggressive SCC-25 cells, were able
to form LYVE-1+ vessel-like network on Matrigel. The
in vivo LM phenomenon was also evident in an orthotopic
mouse model of OSCC. Of note, such LM vessel-like
structures were strongly positive for CD44—a biomarker
implicated in the plasticity of aggressive tumour cells and
VM formation17. These findings support the notion that
the mimicry phenomenon is associated with more
aggressively growing tumours. A function for LYVE-1 as a
lymphangiogenic factor is fully consistent with its evident
expression at the tubular extensions and intercellular
junctions on Matrigel. These in vitro and in vivo findings
suggest that intratumoural CK+/LYVE-1+ lumens in the
clinical samples are likely LM structures rather than
basement membrane sleeves of pruned vessels, as could
be encountered when identifying mimicry structures8,27.
The LYVE-1 is an essential mediator of tumour lym-
phangiogenesis and correlates with lymph node metas-
tasis in HNSCC patients18,26,39. Indeed, LYVE-1-driven
effects are mediated by binding with its ligand—hyalur-
onan (HA). Importantly, HA is synthesised by both
tumour and stromal cells in OSCC, and it has been shown
to regulate various cancer processes from initiation to
metastasis40–42. Thus, it is logical to assume that LYVE-1+
OSCC cells may utilise HA/LYVE-1 interaction to facil-
itate oral carcinogenesis. This assumption is supported by
an interesting study showing that aggressive breast cancer
cells can harness their HA content to bind LYVE-1 and
facilitate adhesion, hence invasion and metastasis43.
Notably, the high-metastatic cells used in our study, HSC-
3, were proven to be highly sensitive and responsive to
(see figure on previous page)
Fig. 4 The siRNA-mediated knockdown of LYVE-1 in HSC-3 cells. a, b The qPCR and western blot analyses showed a clear attenuation of LYVE-1
in the silenced HSC-3 cells. Three Silencer Select Validated siRNAs for silencing LYVE-1 (IDs s21402, s21403 and s21404) were tested along with one
negative control siRNA (cat no. 4390843, all were Ambion by Life Technologies, Carlsbad, CA, USA) in two different final concentrations, 10 and 50 nM.
The siRNA sequences were as follows: (1) s21402: sense 5′-GGAUUUUGCUAUGUCAAAAtt, antisense 5′-UUUUGACAUAGCAAAAUCCaa; (2) s21403:
sense 5′-CCAAAGUAGUAAAGGAGGAtt, antisense 5′-UCCUCCUUUACUACUUUGGtt; and (3) s21404: sense 5′-CAACCCUAAUGAGGAAUCAtt, antisense
5′-UGAUUCCUCAUUAGGGUUGct. For analysis of LYVE-1 gene expression, 15 × 104 HSC-3 cells per well were plated on a 24-well plate in duplicates
for each siRNA and concentrations. The next day the cells were transfected according to the manufacturer’s protocol with the help of Lipofectamine
RNAiMAX (Invitrogen) transfection reagent. After 48 h of transfection, the RNA was extracted with TRizol Plus RNA Purification Kit (Ambion) along with
manufacturer’s instructions and the RNA yield quantified with NanoDrop 2000. The LYVE-1 siRNA 1 (Lot no. AS02DZX5) at a concentration of 10 nM
was determined to be optimal for functional assays. For protein extraction and functional assays, HSC-3 and SCC-25 cells (20 × 104 per well) were
plated on 6-well plate (Corning). The next day, LYVE-1 siRNA 1 and negative control siRNA (siControl) were transfected as described above. After 48 h,
the silenced (siLYVE-1) and siControl cells were collected for protein extraction as described in the supplementary materials; or were detached,
quantified and seeded for the functional experiments as described in the following sections. c HSC-3 cells transfected with siRNA LYVE-1 (siLYVE-1)
were not able to form consistent vessel-like structures on Matrigel compared to siControl cells. The vessel-like tube formation assay was performed as
described previously49. The siLYVE-1 and siControl cells were imaged using the IncuCyte S3™ live cell imaging system (Essen BioScience, Ann Arbor,
MI, USA) with 10x magnification in Standard module (4 images/well) and/or 4x magnification in Whole Well module. d The resazurin assay revealed
that siRNA-mediated knockdown of LYVE-1 caused a modest, non-significant, decrease on the growth of HSC-3 cells (P > 0.05). Briefly, the siLYVE-1
and siControl cells were seeded at a density of 5 × 103 cells/well in a 96-well black plate (Thermo Fisher Scientific), and allowed to attach overnight.
After 24 h, resazurin sodium salt (Sigma-Aldrich, Germany) was added to each well at a final concentration of 3 µg/ml, and incubated for 3 h at
+37 °C. The fluorescence was measured using an excitation wavelength of 560 nm and an emission wavelength of 590 nm using a Victor 3 V
instrument (PerkinElmer Life Sciences, Boston, MA, USA). e, f The IncuCyte scratch-wound healing assay showed that siLYVE-1 HSC-3 cells had a
remarkable and consistent reduction in their directed migration (relative wound density) compared to the siControl HSC-3 cells. AUC area under the
curve. Data were presented as means ± standard deviations. **P ≤ 0.01. The scratch-wound healing assay was performed using the IncuCyte S3TM
imaging system according to the manufacturer’s protocol. The siLYVE-1 and siControl cells were seeded at a density of 30 × 103 cells/well in a 96-well
ImageLockTM tissue culture plate and incubated for 24 h at +37 °C. Next, the WoundMakerTM tool (Essen Bioscience) was used to create
homogenous and consistent scratch wounds and the cells were washed once with PBS to remove dislodged cells and supplemented with 1% FBS
culture media. The wells were imaged in IncuCyte S3™ imaging system using objective with 10x magnification in Scratch-Wound Module every 2–4 h
until the open areas were closed by the tumour cells. g, h Zebrafish xenografts revealed that siControl group had more tumour metastasis to cloaca
and tail areas of the fish compared with the siLYVE-1 group, where tumours remain largely confined within the yolk sac region (61.1 vs. 24.1%,
respectively; P < 0.05). A cutoff value of ≥1 cells that metastasised outside the yolk sac region was considered to discern fish with metastasis. Data
were presented as the mean of three independent experiments ± standard deviation. *P ≤ 0.05. Fish experiments were conducted at the Zebrafish
Unit at the University of Helsinki and approved by the ethical permission from the regional state administrative agency (ESAVI/13139/04.10.05/2017).
Wild-type zebrafish (AB strain) were bred, raised and maintained in laboratory fish multi-rack facility as described earlier50. Two-day post-fertilisation
zebrafish larvae (n= 50 per experiment) were dechorionated, anesthetized with 0.04% Tricaine. Next, siControl or siLYVE-1 HSC-3 cell suspension (4 nl
of 1500 cells/fish), labelled with CellTrace™ Far Red (Thermo Fisher Scientific), was microinjected into the perivitelline space of the anesthetized fish.
Larvae were then maintained in an embryonic medium containing (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2 and 0.33 mM MgSO4; Sigma-Aldrich,
Germany) at 34 °C for three days. On the fourth day post-injection, larvae were collected, fixed with 10% PFA and mounted on slides using SlowFade
Gold Antifade reagent (Invitrogen, California, US). Zebrafish were imaged using Nikon Eclipse Ti-E Camera (Nikon, Tokyo, Japan) and images were
analysed using ImageJ software (Wayne Rasband, NIH, US).
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HA-signalling in vitro44. Here, we have shown that HSC-3
exhibit marked suppression of tube formation, migration
and invasion potential in 3D in vitro models following the
siRNA-mediated knockdown of LYVE-1. More impor-
tantly, inhibition of LYVE-1 in HSC-3 cells significantly
reduced their metastatic potential in zebrafish larvae. In
agreement with our report, it was recently shown that
anti-LYVE-1 monoclonal antibody inhibited primary
tumour formation and metastasis to axillary lymph nodes
in xenograft models of breast cancer16.
Finally, these pieces of evidence may bear considerable
therapeutic implications. Despite the major advances in
the development of new angiogenic inhibitors, the clinical
success of these drugs remains, however, considerably
limited45. As a result, to date there are no FDA-approved
therapeutics that target tumour-related lymphangiogen-
esis46. The de novo formation of tumour-derived mimicry
channels was suggested as a plausible factor that could
reduce the effects of anti-angiogenic therapy23,32. Thus, a
better understanding of LYVE-1 function in tumour cells
and its role in LM formation could benefit the develop-
ment of targeted therapeutics for blocking tumour lym-
phangiogenesis in OSCC. Clearly, more detailed studies,
including larger sample size and complete deletion
models of LYVE-1, are necessary in order for such phe-
nomenon to be better defined in the future.
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